|Day Low/High||68.50 / 74.73|
|52 Wk Low/High||16.61 / 99.45|
Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.
Several stocks spent Monday's trading session in the red, and here's why.
Bristol-Myers Squibb Company (NYSE:BMY) and Clovis Oncology, Inc.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017, after the close of the U.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.
AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million.
Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by...
Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual...
Here are Wednesday's top research calls, including new coverage of Advanced Micro Devices and Transocean, upgrades for Clovis Oncology and ConocoPhillips, and a downgrade for Disney.
Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.
Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.
Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc , where a total volume of 7,551 contracts has been traded thus far today, a contract volume which is representative of approximately 755,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.5% of CLVS's average daily trading volume over the past month, of 1.8 million shares.
Clovis Oncology closed trading below $67 on Tuesday.
Here's a technical look at how to play a number of stocks trending higher with strong volume.
AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in...
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for 2017.